PF-Atlas › Clinical Trials › NCT01135199
Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis
pomalidomide (CC-4047 · Phase 2
Registry ID
NCT01135199
Phase
Phase 2
Status
Withdrawn
Drug / intervention
pomalidomide (CC-4047
Sponsor
Stanford University
Start
2010-04
Locations
1
About this trial
The purpose of this study is to determine the safety and efficacy of pomalidomide over a 12 week duration in the treatment of chronic cough in patients with IPF as measured by a Cough Symptom Diary, Visual Analogue Scale for Cough Severity, Leicester Cough Questionnaire, St. George Respiratory Questionnaire, Cough-Specific Quality-of-Life Questionnaire, and adverse event reporting. There will be an option open to participants, who respond to treatment by meeting pre-determined criteria, to remain in the study for an additional 9 months or for a total of 54 weeks.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01135199 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.